Nano-Formulated Melatonin for Parkinson’s Disease
Nano-formulated melatonin, developed by researchers at INST Mohali, shows promise for treating Parkinson’s Disease (PD) by enhancing mitophagy and reducing oxidative stress in neurons. Using human serum albumin (HSA) as a nanocarrier, this formulation ensures targeted drug delivery to the brain, improving therapeutic efficacy. Preclinical trials demonstrated significant neuroprotection in rat models against rotenone-induced toxicity, primarily through upregulating BMI1, a key epigenetic regulator. This innovative approach not only alleviates symptoms but also addresses underlying causes of PD, offering a safer and more effective treatment option with broad potential for managing neurodegenerative diseases.
If you like this post, please share your feedback in the comments section below so that we will upload more posts like this.
